| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8519392 | Contemporary Clinical Trials Communications | 2017 | 27 Pages |
Abstract
The outcomes of the REDUQ trial will advance knowledge on treatment of smoking COPD patients not ready to quit. If (cost-)effective, the smoking reduction intervention can be offered to this difficult-to-treat target group as a valuable adjunct to smoking cessation treatment.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
Petra Hagens, Marcel Pieterse, Paul van der Valk, Job van der Palen,